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Because raising cAMP enhances 26S proteasome activity and the degradation of cell 
proteins, including the selective breakdown of misfolded proteins, we investigated 
whether agents that raise cGMP may also regulate protein degradation. Treating various 
cell lines with inhibitors of phosphodiesterase 5 or stimulators of soluble guanylyl cyclase 
rapidly enhanced multiple proteasome activities and cellular levels of ubiquitinated 
proteins by activating Protein Kinase G (PKG).  PKG stimulated purified 
26S proteasomes by phosphorylating a different 26S component than is modified by 
Protein Kinase A. In cells and cell extracts, raising cGMP also enhanced within minutes 
ubiquitin conjugation to cell proteins. Raising cGMP, like raising cAMP, stimulated the 
degradation of short-lived cell proteins, but unlike cAMP, also markedly increased 
proteasomal degradation of long-lived proteins (the bulk of cell proteins) without affecting 
lysosomal proteolysis. We also tested if raising cGMP, like cAMP, can promote the 
degradation of mutant proteins that cause neurodegenerative diseases. Treating 
zebrafish models of tauopathies or Huntington’s disease with a PDE5 inhibitor reduced 
the levels of the mutant huntingtin and tau proteins, cell death, and the resulting 
morphological abnormalities. Thus, PKG rapidly activates cytosolic proteasomes, protein 
ubiquitination and overall protein degradation, and agents that raise cGMP may help 




Most studies of the regulation of proteolysis by the ubiquitin proteasome system have 





26S proteasome and rates of protein degradation in cells are also tightly regulated 
through proteasome phosphorylation. Here we demonstrate that agents that raise cGMP 
and activate cGMP-dependent protein kinase (e.g. widely-used phosphodiesterase 5 
inhibitors) stimulate proteasome activities and intracellular proteolysis without affecting 
autophagy. Furthermore, we showed that raising cGMP reduced the levels of the 
disease-causing mutant tau in a zebrafish model by increasing its degradation, and also 
decreased the associated morphological abnormalities. Thus, activating the proteasome 







In mammalian cells, the great majority of proteins are degraded by the ubiquitin 
proteasome system (UPS) (1). These proteins are targeted for degradation by linkage to 
a ubiquitin chain and are then hydrolyzed by the 26S proteasome. Because of the very 
large number of enzymes specifically involved in ubiquitinating different substrates, and 
the many cellular processes that are regulated by ubiquitination of key proteins, it is 
generally assumed that a protein’s rate of degradation is determined solely by its rate of 
ubiquitination. However, there is growing evidence that protein half-lives are also 
influenced by changes in proteasome activity, as occur in various physiological and 
pathological conditions (1, 2). One form of proteasome regulation that has been recently 
established to be physiologically important and therapeutically promising is the 
phosphorylation of proteasome subunits (2). A number of kinases have been reported to 
alter proteasome activities (2), including CAMKII (3), ASK1 (4, 5), Aurora B (6), p38 





have clear effects on intracellular protein degradation and to enhance proteasome 
function via subunit phosphorylation: DYRK2 (11, 12) and Protein Kinase A (13-15). 
cAMP and PKA were shown to increase the ability of purified 26S proteasomes 
to hydrolyze polyubiquitinated proteins, ATP, and small peptides via phosphorylation of 
Serine 14 in Rpn6, a subunit of the 19S regulatory complex (13, 15). Activating PKA with 
pharmacological agents that increase cAMP synthesis by adenylyl cyclases or inhibit its 
breakdown by phosphodiesterase 4 (PDE4) stimulated the selective degradation of 
short-lived cell proteins, which include misfolded and many regulatory proteins, but not 
the long-lived cell constituents, which comprise the bulk of cell proteins (13). A similar 
activation of proteasomes and protein degradation in vivo by PKA also occurs in 
response to various endocrine stimuli that act by raising cAMP levels (15). For example, 
proteasome activity, Rpn6-S14 phosphorylation, and the breakdown of short-lived 
proteins are all enhanced in mouse hepatocytes after exposure to glucagon or 
epinephrine and in kidney cells by vasopressin (15). Proteasome activity also increases 
by this mechanism in livers and skeletal muscles of mice when cAMP levels increased 
during a brief fast and in skeletal muscles of humans and rats upon intense exercise 
(15). Also, the ability of PKA to stimulate the degradation of misfolded proteins has 
therapeutic promise because pharmacological agents that raise cAMP enhanced the 
capacity of cultured cells (13) and mouse brains (14, 16) to destroy misfolded proteins, 
such as mutant forms of tau that cause Frontotemporal Dementia. In the present study, 
we demonstrate that raising cGMP and activating the cGMP-dependent kinase (PKG) 
can also stimulate 26S proteasomes and protein degradation, but in a manner distinct 
from PKA, and that these treatments also have beneficial effects in models of 





cGMP is an intracellular second messenger that is synthesized by soluble 
guanylyl cyclases in response to nitric oxide (17) or by transmembrane guanylyl 
cyclases in response to peptide hormones, such as natriuretic peptides (18). Most 
interest in cGMP has focused on its role in mediating smooth muscle relaxation and 
vasodilation, and many agents that raise cGMP are used clinically because of their 
beneficial effects on cardiovascular function. Inhibitors of phosphodiesterase 5 (PDE5) 
(e.g. sildenafil or tadalafil), which raise cGMP by blocking its hydrolysis to GMP, are 
widely used for the treatment of erectile disfunction and pulmonary hypertension (19), 
and stimulators of soluble guanylyl cyclases (e.g. vericiguat or riociguat), which stimulate 
cGMP synthesis, are used as treatments for pulmonary hypertension and heart failure 
(17).  
Although the ability of these agents to alter protein turnover generally or to 
combat the progression of neurodegenerative disease has received little or no attention, 
in a mouse model of a cardiomyopathy caused by overexpression of mutant αβ 
crystallin, raising cGMP with sildenafil was shown to reduce cardiac hypertrophy (10). 
This treatment also raised proteasomal peptidase activity in the heart and reduced the 
levels of mutant αβ-crystallin (10). These findings suggested that agents that raise 
cGMP may have therapeutic potential in hereditary cardiomyopathies. However, it was 
not clear whether these effects of cGMP on proteasomes are specific to the heart, 
whether PKG directly activates proteasomes, or whether cGMP may enhance 
intracellular protein breakdown generally and may also influence protein ubiquitination or 
autophagy. 
Here we have systematically investigated whether different pharmacological 





different classes of cell proteins. These studies demonstrate that PKG stimulates 
multiple 26S proteasome activities by phosphorylation of a different proteasome 
component than is modified by PKA. Also, unlike cAMP, cGMP stimulates the 
degradation of the bulk of cell proteins, and not just short-lived proteins. Because of 
these large increases in protein degradation, we also studied whether raising cGMP 
increases protein ubiquitination and autophagy. A number of major neurodegenerative 
diseases are caused by the accumulation of misfolded or mutant proteins, and in many 
cases the buildup of such aggregation-prone proteins impairs proteasome function, 
which leads to further defects in protein homeostasis (14, 20, 21). Because of the 
therapeutic potential of stimulating proteasome activity and enhancing the breakdown of 
disease-associated proteins, we also tested in zebrafish larvae models of tauopathies 
and Huntington’s disease whether raising cGMP or cAMP can stimulate the degradation 





Pharmacological agents that raise cGMP stimulate 26S proteasome activities 
To raise the intracellular levels of cGMP, we used two inhibitors of PDE5, 
tadalafil or sildenafil, and two stimulators of soluble guanylyl cyclases, BAY41-2272 or 
cinaciguat. Addition of tadalafil (100 nM) or BAY41-2272 (100 nM) to human 
neuroblastoma cells (SH-SY5Y) caused a rapid increase in the proteasomes’ 
chymotrypsin-like peptidase activity in cell lysates (Figure 1A). This increase was evident 
by 5 minutes after the addition of tadalafil or BAY41-2272 and was maximal at 30 
minutes (Figure 1A). As expected, the addition of tadalafil and BAY41-2272 together 





(Figure 1A). This activity decreased between 30 to 90 minutes after addition, although it 
remained above control levels at 90 minutes (Figure 1A).  
This rapid stimulation and slow decline of peptidase activity occurred without any 
change in the levels of proteasome subunits (Figure 1B). Also, this cGMP-mediated 
stimulation of proteasome activity was not due to an increase in the assembly of the 26S 
proteasomes. When SH-SY5Y cells were treated with tadalafil, no change in the amounts 
of singly- or doubly-capped 26S proteasomes was seen at 15 minutes or 2 or 4 hours 
later, as measured by native PAGE and Western blot (Figure 1C). 
To verify that these increases in peptide hydrolysis were due to greater 26S 
proteasome activity, SH-SY5Y cells were treated for 30 minutes with tadalafil, BAY41-
2272, or these two agents together, and the 26S proteasomes were then purified using 
the UBL domain as the affinity ligand (22). The proteasomes from cells treated with 
tadalafil or BAY41-2272 exhibited 60–80% greater chymotrypsin-like activity, and the 
particles from cells incubated with both agents were approximately twice as active as 
those from control cells (Figure 1D). Similar increases were also seen in the 26S 
proteasome’s caspase-like and trypsin-like activities (Figure 1D). This coordinated 
enhancement of all three peptidase activities strongly suggests that activation involves 
more rapid entry of peptides into the 20S core, as occurs in other types of proteasome 
activation (23), rather than a stimulation of individual active sites.  
The physiological substrates of 26S proteasomes are ubiquitinated proteins, 
whose degradation is linked to ATP hydrolysis (1). The proteasomes isolated from 
tadalafil or BAY41-treated cells showed a greater capacity to hydrolyze ATP (Figure 1E), 
and a polyubiquitinated protein, as assayed using as the substrate the fluorescent 





Thus, raising cGMP increases multiple activities of 26S proteasomes by a post-synthetic 
modification without increasing 26S proteasome assembly. 
PKG activates cytosolic, but not nuclear, proteasomes 
Inhibiting the activation of PKG by treating SH-SY5Y cells with the cGMP analog 
Rp-8-Br-PET-cGMPs blocked the increases in the chymotrypsin-like activity induced by 
tadalafil and BAY41-2272 (Figure 2A). Furthermore, transient overexpression of PKG1 
in HEK293 cells stimulated this activity (Supplemental Figure 1A). Although 26S 
proteasomes are abundant in both the nucleus and cytosol, PKG is localized primarily to 
the cytosol (25)(Supplemental Figure 1B). Therefore, we tested whether activated PKG 
in cells stimulates the activities of proteasomes in both fractions. After treatment of SH–
SY5Y cells with tadalafil or DMSO for 30 minutes and hypotonic lysis, nuclei were 
separated from the cytosol by differential centrifugation and then 26S proteasomes were 
purified from each fraction by the UBL method. After tadalafil treatment, the cytosolic, 
but not the nuclear proteasomes, exhibited greater peptidase activity (Figure 2B). Higher 
levels of protein phosphorylation were detected by western blot for pSer/Thr residues 
that are preceded by the amino acid sequence RRX (Figure 2C). RRXpS/T is a 
consensus motif of PKG (26). Two phosphorylated bands of approximately 130 kDa and 
100 kDa were more intense across all conditions that raised cGMP and thus correlated 
with the increased proteasome activities. Because no proteasome subunit is larger than 
100 kDa, the 130 kDa band must be a proteasome-associated protein. 
Phosphorylation is required for the proteasome activation caused by intracellular 





To verify that phosphorylation of proteasome subunits or a proteasome-
associated protein is responsible for the activation by cGMP and PKG, 26S proteasomes 
were affinity-purified from SH-SY5Y cells after a 30-minute treatment with tadalafil or 
DMSO and incubated with lambda phosphatase. This enzyme reduced the levels of 
phosphorylated proteins (Figure 2D) and eliminated the tadalafil-mediated increase in 
chymotrypsin-like activity (Figure 2E).  
Because PKG may activate proteasomes indirectly in cells by phosphorylating 
another kinase or a cytosolic protein which then might bind and activate the 
proteasomes, we tested whether PKG can phosphorylate and activate the affinity-
purified 26S proteasomes. After incubation of 26S proteasomes from human fibroblasts 
(BJ5A) with increasing concentrations of human PKG1 for 1 hour, the levels of 
phosphorylated bands at 100 and 130 kDa in the proteasome preparations increased in 
a concentration-dependent manner (Fig 2F). There was also a concentration-dependent 
increase in the proteasome’s peptidase activity (Figure 2G). Thus, phosphorylation is 
essential for proteasome activation, and PKG in vitro can stimulate 26S activity by 
phosphorylating a proteasome subunit or a tightly-associated regulatory protein.  
PKG does not phosphorylate Rpn6, Rpt3, or Rpt6 
Prior work has demonstrated that phosphorylation of two sites on the 19S 
regulatory particle increases proteasomal activities: Rpn6-S14 by PKA (13, 15) and 
Rpt3-Thr25 by DYRK2 (11, 12). Using phosphosite-specific antibodies, we tested if 
levels of these phosphorylated subunits increase in 26S proteasomes purified from 
tadalafil- or BAY-412272-treated SH-SY5Y cells. Neither treatment increased the 





HEK293 cells (Supplemental Figure 1C). However, the overexpression of PKG did 
increase the amount of phosphorylated proteins detected in the proteasome 
preparations above levels in particles from cells transfected with an empty vector. In 
addition, the over-expressed PKG co-purified with the 26S proteasomes (Supplemental 
Figure 1C). Similar increases in the levels of phosphorylated proteins and the amount of 
PKG that co-purified with proteasomes was seen after treatment of HEK293 cells with 
the soluble guanylyl cyclase stimulator cinaciguat (Supplemental Figure 1D).  
The subunit Rpt6 has also been reported to be phosphorylated by PKG (10) and 
on S120 by CAMKII (3). However, using an antibody specific for phosphorylated Rpt6-
S120 (27), we found no change in phosphorylation of this site in proteasomes purified 
from tadalafil- or BAY41-2272-treated SH-SY5Y cells (Figure 2H). Thus, PKG directly 
stimulates proteasomal activity by phosphorylation of a 26S subunit or a protein that co-
purifies with the 26S particle, that is not presently known to regulate proteasome 
function. 
Raising cGMP stimulates degradation of both short-lived and long-lived cell 
proteins   
Raising the level in cells of cAMP with pharmacological agents or hormones 
enhances selectively the degradation of short-lived proteins (13, 15), which include 
misfolded, damaged, and regulatory proteins, but does not alter the breakdown of long-
lived proteins, which comprise the bulk of cell components. To determine whether cGMP 
and PKG also stimulate the degradation of short-lived proteins, SH-SY5Y cells were 
incubated with 3H-phenylalanine for 20 minutes to label short-lived proteins. After the 3H-
phenylalanine was removed, fresh media containing large amounts of non-radioactive 





amino acids released by proteolysis. The degradation of the labeled proteins was then 
measured by assaying the generation of radiolabeled amino acids (28). Adding tadalafil 
or BAY41-2272 after the incorporation of 3H-phenylalanine increased the rate of 
degradation of the most short-lived proteins, and combining these two agents led to an 
even greater increase in their degradation (Figure 3A). A similar increase in degradation 
of short-lived proteins was seen in SH-SY5Y cells with tadalafil, cinaciguat, and a 
combination of these two agents (Supplemental Figure 2A).  
To determine whether raising cGMP also stimulates the degradation of damaged 
or misfolded proteins, which are short-lived, we induced the production of incomplete 
proteins by exposing SH-SY5Y cells for 1 hour to puromycin, which is incorporated into 
newly synthesized proteins and causes premature termination of the polypeptides which 
are then rapidly hydrolyzed (29). Degradation of the puromycyl polypeptides was 
followed in the presence of cycloheximide by western blot for puromycin. Adding tadalafil 
with the cycloheximide reduced the amount of puromycin-containing proteins below the 
levels in control cells (Supplemental Figure 3A). Thus, cGMP and PKG enhance the 
degradation of these abnormal polypeptides. 
These increases in proteolysis presumably also reflect accelerated degradation 
of many short-lived regulatory proteins. Therefore, we measured by western blot the 
degradation in the presence of cycloheximide of p53, whose rapid ubiquitination and 
degradation have been extensively characterized (30). The breakdown of p53 was also 
increased by treatment with tadalafil or BAY41-2272 (Supplemental Figure 3B). 
To evaluate whether raising cGMP also increases the degradation of the bulk of 
cell proteins, which are long-lived components, SH-SY5Y cells were incubated with 3H-





allow the hydrolysis of labeled short-lived proteins, and then the degradation of the 3H-
labeled long-lived proteins was measured (31). Addition of tadalafil or cinaciguat after 
the 2-hour chase, increased the rate of degradation of long-lived proteins by 30–50%, 
and a combination of the two agents caused an even larger (~2-fold) increase in the 
overall rate of proteolysis (Figure 3B). A similar stimulation of proteolysis was seen in 
SH-SY5Y with sildenafil and BAY41-2272 and also in C2C12 mouse myotubes 
(Supplemental Figure 4A and 4B). These rates of degradation of long-lived proteins 
were linear for at least four hours and were surprisingly high. In fact, these rates were 
greater than those seen in such cells upon serum or nutrient deprivation (31), and the 2-
fold increase with tadalafil and cinaciguat together exceeds rates of degradation seen in 
highly catabolic conditions (e.g. muscle atrophy or cachexia) (32). Thus, raising cGMP, 
like raising cAMP, stimulates the degradation of short-lived proteins, but unlike cAMP, it 
also increases degradation of the long-lived fraction.  
The cGMP-mediated increase in protein degradation required PKG because it 
could be blocked in SH-SY5Y cells either by knockdown of PKG1 with siRNA (Figure 
3C; Supplemental Figure 4C) or by inhibition of PKG with Rp-8-Br-PET-cGMPs (Figure 
3D). Furthermore, the overexpression in HEK293 cells of PKG1α increased the 
degradation of long-lived proteins (Figure 3E). By contrast, overexpression of PKA’s 
catalytic subunit did not enhance the degradation of those long-lived proteins, in accord 
with our prior findings (13, 15). Thus, increasing PKG activity is necessary and sufficient 
for the cGMP-mediated increase in protein degradation. 
The neurotransmitter, acetylcholine, raises levels of cGMP via M2 muscarinic 
receptors and treating cultured rat cardiomyocytes with M2 agonists was reported to 





via M2 muscarinic receptors also stimulates total protein breakdown in cells, we used 
the immortalized human foreskin fibroblast cell line, BJ5A-hTERT, which expresses M2 
muscarinic receptors but not other muscarinic or nicotinic receptors 
(humanproteinatlas.org). In these cells, as in other lines tested, cinaciguat stimulated the 
degradation of both short- and long-lived proteins (Supplemental Figures 5A + 5B). 
Surprisingly tadalafil by itself did not increase protein degradation in these cells 
(Supplemental Figures 5A + 5B) or in HEK293 cells (Supplemental Figures 5C + 5D), 
probably due to a low level of basal cGMP synthesis. However, combining cinaciguat 
with tadalafil in BJ5A and HEK293 cells produced even larger increases in proteolysis 
(Supplemental Figures 5A - 5D). Treating BJ5A cells with carbachol, a pan muscarinic 
receptor agonist, stimulated the degradation of both short- and long-lived proteins 
(Figures 3F + 3G), and these rates could be further increased if tadalafil was also 
present (Figures 3F + 3G). These observations with carbachol suggest that an increase 
in degradation occurs in vivo when cGMP is raised by cholinergic stimuli.  
Raising cGMP stimulates proteasomal degradation but not autophagy 
Long-lived cell proteins are degraded primarily by the ubiquitin proteasome 
system, but also by autophagy (31). To determine the contribution of each pathway to 
the cGMP-mediated increase in overall protein breakdown, a specific irreversible 
inhibitor of the proteasome, carfilzomib, was included in the chase period to measure 
degradation by lysosomes, or an inhibitor of lysosomal acidification, concanamycin A, to 
measure proteasomal degradation (28). Tadalafil and cinaciguat alone or together 
stimulated protein degradation to a similar extent in the presence of concanamycin A, 
and thus they clearly promote proteasomal proteolysis (Figure 3H). By contrast, neither 





inhibited (Figure 3I). Thus, the stimulation of overall protein breakdown by PKG occurs 
through a selective increase in proteolysis by the proteasomes. 
cGMP increases levels of ubiquitinated proteins by stimulating ubiquitin 
conjugation  
Because raising cGMP causes such large increases in proteasomal degradation, 
we also tested whether these treatments in addition to stimulating proteasome activities 
might enhance the ubiquitination of cell proteins. Surprisingly, adding tadalafil or BAY41-
2272 to SH-SY5Y cells increased within 5 minutes the total cellular content of 
ubiquitinated proteins (Figure 4A). This increase in ubiquitinated proteins was maximal 
30 minutes after exposure to either agent and then decreased during the subsequent 60 
minutes, although the level of ubiquitin conjugates still remained higher than in control 
cells (Figure 4A). Combining tadalafil and BAY41-2272 also raised the levels of ubiquitin 
conjugates within 5 minutes, but the maximal increase (2-fold) was not reached until 60 
minutes (Figure 4A). Surprisingly, this accumulation of polyubiquitinated proteins with 
the combined treatment appeared slower than with either agent alone, perhaps because 
of the faster activation of proteasomes (Figure 1A) and greater degradation of 
ubiquitinated proteins (Figure 3). In fact, the changes shown in Figure 4A must 
underestimate the actual increase in levels of ubiquitin conjugates due to the 
simultaneous enhancement of proteasomal degradation. Accordingly, when SH-SY5Y 
cells were treated with the agents that raise cGMP plus the proteasome inhibitor 
bortezomib for 15 minutes, the levels of ubiquitinated proteins increased even further 
(Figure 4B). Tadalafil treatment for 30 minutes in SH-SY5Y cells also increased the 





and where proteasomes are activated (Figure 2B), and not in the nuclear fraction (Figure 
4C).  
To determine whether the increased levels of polyubiquitinated proteins were due 
to increased ubiquitination or decreased deubiquitination of cell proteins, we used 
cytosolic extracts from HEK293 cells from which nuclei and mitochondria were 
sequentially removed by differential centrifugation. Incubating these extracts with 1 µM 
cGMP for 30 minutes in the presence of the broad-spectrum phosphodiesterase inhibitor 
IBMX activated PKG, as shown by increased phosphorylation of VASP (Supplemental 
Figure 6A; Figure 4D), a well-characterized PKG substrate, and increased proteasomal 
peptidase activity (Supplemental Figure 6B), as also seen upon treatment of cells with 
agents that raise cGMP (Figure 1) and incubation of purified 26S particles with PKG (Fig 
2G). Addition of cGMP to the extracts in the presence of bortezomib to inhibit 
proteasomes, 1,10-phenanthroline to inhibit metallo-deubiquitinases, and PR-619 to 
inhibit a broad spectrum of deubiquitinases (33) increased the levels of polyubiquitinated 
proteins and K48-linked polyubiquitinated proteins, strongly suggesting a stimulation of 
protein ubiquitination (Figure 4D). By contrast, cGMP did not change the levels of K63-
linked or K11-linked polyubiquitinated proteins (Supplemental Figure 7A).  
To evaluate whether cGMP also decreases the rate of deubiquitination of cell 
proteins, HEK293 cells were treated for 30 minutes with bortezomib to increase the 
levels of ubiquitinated proteins and cytosolic extracts were prepared as above, but in the 
presence of an inhibitor of the ubiquitin activating enzyme instead of the inhibitors of 
deubiquitinases. Adding cGMP to these extracts did not change the rate of 
deubiquitination of cell proteins (Figure 4E). Furthermore, cell lysates prepared from SH-





greater deubiquitinating activity than control, as measured by the covalent modification 
of the active sites of DUBs with HA-Ub-VS (Supplemental Figure 8A) and the hydrolysis 
of ubiquitin-amc (Supplemental Figure 8B). Thus, cGMP increases the levels of 
polyubiquitinated proteins by stimulating the ubiquitination of cell proteins more than it 
enhances their degradation by proteasomes. 
Raising cGMP or cAMP reduces pathology in zebrafish models of 
neurodegenerative diseases 
Many neurodegenerative diseases are caused by an accumulation of 
aggregation-prone misfolded proteins, and there is growing evidence in experimental 
models of these disease that such proteins lead to impaired proteasome activity and a 
reduced cellular capacity for protein breakdown (14, 20). Agents that raise cAMP appear 
to be promising therapies for proteotoxic diseases through their ability to enhance 
proteasome activity and the degradation of such toxic proteins (13, 14, 16). Because 
cGMP can also activate proteasomes and enhance protein degradation, we tested 
whether raising cGMP might also help clear these aggregation-prone proteins and thus 
reduce the resulting pathology in zebrafish models of tauopathies and Huntington’s 
Disease. To determine whether raising cGMP or cAMP can activate proteasomes in 
zebrafish, larvae were exposed to sildenafil (1 and 10 µM), rolipram (3 and 30 µM), or 
DMSO for 5 days. Proteasomes purified by the UBL method from larvae treated with 
either concentration of sildenafil or rolipram exhibited greater chymotrypsin-like activity 
than those from the DMSO-treated or untreated larvae (Supplemental Figure 9C). 
Furthermore, exposure to these agents for only one day also increased proteasomal 





At these concentrations, neither drug had any overt toxic effects on the larvae 
(data not shown). There was also no change in the levels of proteasome subunits in the 
lysates of the larvae, and the treatments (Supplemental Figure 9A) with 1 µM sildenafil 
or 3 µM rolipram did not alter the levels of assembled 26S proteasomes in the lysates 
measured by native PAGE and western blot (Supplemental Figure 9B). In these lysates, 
unlike those of human cells (Figure 1C), the singly-capped 26S proteasomes ran as a 
doublet on native PAGE (Supplemental Figure 9B). Treatment with 10 µM sildenafil or 
30 µM rolipram, but not with the lower concentrations of either agent, increased the 
intensity of the upper band of the doublet and decreased the intensity of the lower band 
(Supplemental Figure 9B). This interesting effect, however, did not correlate with 
changes in activity because 26S proteasomes from larvae treated with 1 or 10 µM 
sildenafil or 3 or 30 µM rolipram showed similar increases in peptidase activity 
(Supplemental Figure 9C). 
Because raising cGMP and cAMP activate 26S proteasomes via post-synthetic 
modification in zebrafish, as in mammalian cells, we investigated their possible effects in 
models of neurodegenerative diseases. The A152T mutation in tau greatly increases the 
risk of developing Frontotemporal Dementia in humans (34), and expression of this 
mutant tau in the nervous system of zebrafish larvae causes neurodegeneration, an 
accumulation of hyper-phosphorylated tau, as occurs in human tauopathies, and 
impairment of proteasomal peptidase activity in the lysates (35) (Figure 5A). However, 
exposure to sildenafil or rolipram for 1 day stimulated proteasomal peptidase activity 
towards the levels in vehicle-treated wild type larvae (Figure 5A).  
To determine whether these treatments also enhanced the degradation in vivo of 





green to red, and then the larvae were treated with sildenafil or rolipram. The amount of 
red mutant tau was assayed in individual spinal cord neurons 6 hours after 
photoconversion. Both sildenafil and rolipram increased the degradation of mutant tau 
(Figure 5B). In addition, these treatments reduced the levels of hyperphosphorylated tau 
detected by western blot relative to the total amount of tau (Figure 5C) (Supplemental 
Figure 10A). Most of the zebrafish larvae expressing the A152T mutant tau in the 
nervous system exhibit an abnormal curvature of the dorsal spine (35) with 50% having 
spinal curvature that was classified as moderate and 25% as severe (Figure 5D). 
Treatment with either sildenafil or rolipram for 2 days increased the percentage of the 
clutch with no curvature from 25% to 40-50% (Figure 5D) and decreased the percentage 
of larvae with a severe curvature from 25% to approximately 10% (Figure 5D). Thus, 
both sildenafil and rolipram not only restored proteasomal activity, but also reduced the 
levels of pathological tau and the associated morphological defects caused by A152T 
tau. 
Overexpression in the zebrafish retina, under the rhodopsin promoter, of human 
WT tau or the P301L mutant tau, which also causes Frontotemporal dementia, leads to 
degeneration and death of the rod photoreceptors (36). To determine if raising cGMP or 
cAMP could prevent this cell death, fish larvae overexpressing either Rho::EGFPTauWT 
or Rho::EGFPTauP301L were exposed to sildenafil or rolipram for five days and the 
photoreceptors detected in the central retina were counted. Both treatments increased 
the number of rod photoreceptors (Figure 5E and Supplemental Figure 10B). 
Furthermore, the degree of rod photoreceptor degeneration was determined by 
analyzing the ratio of the rod protein ZPR3 (rhodopsin) to the cone protein ZPR1 





compared to that seen in siblings that received only the vehicle (Figure 5F; 
Supplemental Figure 10C), indicating that these agents prevented the degeneration 
phenotype. This effect was not due to decreased expression of the transgene, because 
these treatments did not change the levels of EGFP mRNA measured by RT-qPCR 
(Supplemental Figure 10D). 
In Huntington’s Disease, mutant huntingtin containing an expanded 
polyglutamine repeat accumulates in protein aggregates within neurons. To test whether 
raising cAMP or cGMP could also reduce the levels of such aggregates, zebrafish larvae 
expressing exon 1 of human huntingtin with 71 glutamine repeats in rod photoreceptor 
cells (Rho::EGFP-HD71Q) were treated for five days with sildenafil or rolipram, and the 
number of microscopically visible aggregates in the retina was measured. Both agents 
reduced the number of huntingtin aggregates (Figure 5G). Thus, these agents can 
activate proteasomes, enhance the clearance of aggregation-prone proteins, and reduce 




A novel mechanism for regulating overall protein breakdown in cells 
The regulation of protein breakdown by cGMP and PKG differs in several respects 
from other known mechanisms that control intracellular proteolysis. Pharmacological 
agents that inhibit PDE5 or stimulate soluble guanylate cyclase rapidly increase not only 
the activities of 26S proteasomes, but also the levels of ubiquitinated proteins and the 
total rate of intracellular protein degradation. Raising cGMP content even further by 
combining these treatments caused a further increase in the magnitude, rapidity and 
duration of these responses. The increase in ubiquitin conjugates, proteasomal 





these drugs to cultured cells and these changes occurred too rapidly to result from 
changes in gene transcription. It is noteworthy that these increases in proteasomal 
activity and ubiquitinated proteins were only observed in the cytosol, where PKG is 
localized, not the nucleus. The stimulation of proteasome activity and protein turnover by 
cGMP and PKG appears to be a general cellular response because similar changes 
were seen in HEK293, neuroblastoma, myotubes, and fibroblasts, as well as zebrafish 
larvae. However, cell types differ widely in their content of phosphodiesterases and 
guanylate cyclases and in the physiological factors that promote cGMP synthesis. 
Therefore, it remains to be determined to what extent in different tissues, hormones (e.g. 
natriuretic peptides), signaling molecules (e.g. NO), neurotransmitters (e.g. 
acetylcholine), or drugs that raise cGMP also stimulate proteasome function and overall 
proteolysis by the UPS. 
Although both cGMP and cAMP enhance proteasome activity and the degradation of 
short-lived proteins, they probably do not stimulate the ubiquitination and degradation of 
the same short-lived proteins. cGMP and cAMP are generated in different physiological 
states and often have opposite effects on cell function, especially in the cardiovascular 
system. In hearts, epinephrine via cAMP increases cardiac output, while acetylcholine 
via M2 muscarinic receptors raises cGMP and decreases cardiac output. PKG’s ability to 
also stimulate the breakdown of the bulk of cell proteins clearly distinguishes its effects 
on protein degradation from those of PKA and must have important physiological 
consequences. For example, in hearts, adrenergic agonists via cAMP induce 
hypertrophy (37), while agents that raise cGMP reduce this pathologic process (38). The 
capacity of cGMP to increase the overall breakdown of cell proteins may contribute to 





The increases in overall degradation by the UPS with these pharmacological 
treatments were surprisingly large and even exceeded the increases in proteolysis 
reported in cells in various catabolic states, such as cachexia and muscle atrophy (29) or 
upon heat shock (37). The approximately 2-fold increase in total proteolysis induced by 
the combination of sildenafil and cinaciguat is also much larger than the 40-60% 
increases seen typically in cultured cells upon serum deprivation (31) or mTOR inhibition 
(28), both of which stimulate proteolysis primarily by increasing autophagy with only 
about  a 20% enhancement in proteasomal degradation (28). Such a large cGMP-
induced increase in total protein degradation, if maintained, should by itself lead to a 
clear decrease in cell mass within a few days, depending on the cell’s rate of protein 
synthesis.  However, a net loss of cell proteins may not develop if rates of protein 
synthesis are also stimulated by cGMP, or if the effects on proteasomes and protein 
degradation are not maintained. Clearly, our findings raise the possibility that in certain 
catabolic states or during cellular transitions, cGMP may signal a global increase in 
proteolysis and thus influence cell size and composition. 
Activation of proteasomal function through phosphorylation by PKG 
A variety of protein kinases have been reported to alter proteasome activities (2), 
although only three, PKA (13, 15), DYRK2 (11), and now PKG, have been shown to 
activate 26S proteasomes by phosphorylation and to promote intracellular protein 
degradation. The findings that phosphatase treatment reverses proteasome activation by 
cGMP in cells and that incubation with pure PKG causes activation of purified 
proteasomes clearly demonstrate that the stimulation of proteasome activities involves 
direct phosphorylation by PKG of a 26S subunit or a 26S-associated regulatory protein. 





known to regulate proteasome activities, because after activation by PKG in vitro or in 
cells, no change was seen with antibodies specific for the three phosphopeptides 
reported to increase proteasome activities,  Rpn6-S14 (13, 15), Rpt3-Thr25 (11), or 
Rpt6-S120 (27). However, despite repeated attempts, we have been unable thus far to 
identify the proteasomal protein modified by PKG by various mass spectrometric 
approaches. For reasons that remain unclear, the identification of the critical 
phosphorylated site(s) on proteasomes has proven surprisingly difficult for us and for 
other investigators (5).  
It has been claimed that increases in proteasome activity are associated with or even 
require greater formation of 26S proteasomes (39). However, raising cGMP levels by 
several approaches did not change the levels of proteasome subunits or the content of 
doubly- or singly-capped 26S particles. Thus, the increase in proteasome activity is not 
due to the synthesis or assembly of new proteasomes but through a post-synthetic 
modification of pre-existent 26S particles.  
Because these PKG-induced changes in proteasome activities resemble those 
induced by PKA, it is unclear (13, 15) how similar alterations in proteasome activity can 
lead to the distinct effects of PKG and PKA on proteolysis in cells —i.e. how both 
kinases can stimulate the degradation of short-lived fraction of cell proteins, but only 
PKG enhances the breakdown of long-lived components. Possibly, after phosphorylation 
by PKA or PKG, proteasomes differ in their capacity to hydrolyze these different classes 
of ubiquitinated cell proteins. Ubiquitinated short-lived proteins seem to differ from other 
ubiquitin conjugates in containing more branched ubiquitin chains (40) and perhaps also 
differ in their ease of unfolding or mode of delivery to the proteasome. Alternatively, 





of long-lived proteins.  Instead, PKG (unlike PKA) may promote the degradation of long-
lived proteins by increasing their ubiquitination. Also, although these two signaling 
systems both enhance the degradation of short-lived cell proteins, they may stimulate 
ubiquitination and hydrolysis of distinct populations of such proteins.  
It is noteworthy that after a rise in cGMP, the cell’s content of ubiquitinated proteins 
increased, despite the enhanced proteasomal destruction of ubiquitinated proteins and 
total proteolysis by the UPS.  Increases in the levels of ubiquitin conjugates are often 
interpreted as evidence of proteasome inhibition. However, the rapid rise in ubiquitin 
conjugates with PKG activation implies that the increase in protein ubiquitination must 
have exceeded the increase in their degradation. A similar rise in ubiquitin conjugates 
also occurs in atrophying muscles and during starvation despite the activation of 26S 
proteasomes and the increased proteolysis by the UPS (32).  Thus, in many conditions 
where there is a global increase in ubiquitination, proteasomes may also be activated to 
handle the increased substrate load. 
Potential Applications in Combatting Neurodegenerative Diseases 
A large variety of neurodegenerative diseases result from the accumulation of 
misfolded, aggregation-prone proteins, which are generally found in intracellular 
inclusions conjugated with ubiquitin. This buildup of proteins likely represents a failure of 
the cell’s protein quality control machinery.  In fact, there is growing evidence that such 
aggregates or microaggregates can impair the functioning of the 26S proteasomes (14, 
20, 21), as was also shown here (Figure 5) and previously (33) in a zebrafish model of 
tauopathy. The decrease in protein degradation should cause a further accumulation of 
misfolded proteins and eventually disrupt protein homeostasis. Therefore, drugs that 





proteins are an attractive approach to combat the progression of proteotoxic diseases. 
Accordingly, agents that raise cAMP promote the clearance of disease-associated Tau 
mutants in cells (13), and in a mouse model of frontotemporal dementia, where they not 
only increased proteasome activity but also lowered the levels of phospho-tau in the 
brain (14, 16).  Similar effects of rolipram on proteasome activity and phospho-tau 
accumulation were observed here after treatment of the zebrafish model of tauopathy 
caused by overexpression of A152T-tau. 
Surprisingly, raising cGMP with sildenafil had very similar effects in these zebrafish 
larvae as rolipram, not only in the tauopathy models but also in a Huntington’s Disease 
model caused by the expression of a huntingtin exon 1 with a highly expanded polyQ 
sequence.  Although PKA and PKG have very different physiological actions, their key 
shared property in these responses must be their capacity to enhance the degradation of 
short-lived misfolded proteins by the UPS. Remarkably, both sildenafil and rolipram, 
while enhancing proteasome activity and tau degradation, reduced neuronal death and 
the gross morphological abnormalities caused by overexpression of mutant tau in 
neurons. Also, the treatments did not have any evident deleterious consequences, 
probably because they simply augment a physiological mechanism for protein quality 
control. While activation of PKG and PKA reduced the levels of the aggregated proteins, 
these structures are generally much larger than proteasomes. So, it remains unclear 
whether proteasomal digestion involves faster degradation of these misfolded proteins 
before they aggregate, or whether the proteasomes can extract ubiquitinated proteins 
from such aggregates for degradation. It also remains unclear whether these beneficial 
effects result solely through proteasome activation or through enhanced ubiquitination of 





Thus, agents that raise cGMP in the central nervous system represent a promising 
new strategy to combat Alzheimer’s, Huntington’s, and other neurodegenerative 
diseases. In humans, the PDE5 inhibitors and the soluble guanylyl cyclase stimulators 
used here poorly cross the blood brain barrier. However, brain-penetrant PDE5 inhibitors 
(41) and sGC stimulators (17) have been recently reported and inhibitors of other 
phosphodiesterases may also raise cGMP levels in parts of the CNS. Furthermore, 
patients with Alzheimer’s disease have lower levels of cGMP in their cerebrospinal fluid 
(42, 43) and greater expression of PDE5 in the temporal cortex (43) than healthy, age-
matched controls. Thus, a reduction in cGMP signaling in the brain may contribute to the 
progression of Alzheimer’s disease in humans by decreasing ubiquitination, proteasome 
activity, and degradation of misfolded proteins.   
The present findings and other’s prior observations on a mouse model of 
cardiomyopathy caused by an αB crystallin mutation (10, 44) demonstrate the 
therapeutic potential of treatments that raise cGMP to combat diverse proteotoxic 
diseases. Protein damage has also been reported to accompany other diseases, 
including cardiac failure and ischemia (45). The ability of PKG to enhance global protein 
degradation by the UPS may also contribute to its reported benefits in such conditions 
(46). Thus, the activation of PKG is a promising new approach to combat the 
progression of a variety of presently untreatable proteotoxic diseases. 
 
Materials and Methods 
 
Reagents: Tadalafil, Sildenafil, Cinaciguat, BAY41-2272, KT-5823, and Rp-8-pCPT-
cGMPs were purchased from Cayman Chemical, puromycin, cycloheximide, 1,10-





Cruz, Carfilzomib and Bortezomib from UBPBio, λ-phosphatase from New England 
Biosciences, L-[3,4,5-3H]-phenylalanine from American Radiolabeled Chemicals, PR-
619 from Selleckchem, cyclic GMP from Promega, and PKG1α and Ubiquitin-amc from 
ThermoFisher Scientific. Rolipram and sildendafil used in zebrafish experiments were 
purchased from Tocris. 
Cell Lines: All cell lines were obtained from ATCC. HEK293 and BJ5A cells, and C2C12 
myoblasts, were cultured in DMEM supplemented with 10% FBS. C2C12 were 
differentiated into myotubes for 5 days in DMEM supplemented with 2.5% horse serum. 
SH-SY5Y cells were cultured in DMEM/F12 supplemented with 10% FBS.  
Cell lysis and immunoblot: After treatments, cells were washed twice in cold PBS and 
then flash frozen on dry ice. The cells were lysed in the following buffer: 25 mM HEPES-
KOH pH 7.5, 150 mM NaCl, 2.5 mM EDTA, 0.3% CHAPS, 10 mM N-Ethylmaleimide, 0.5 
mM PMSF, 1 μM MG-132, 1 mM NaF, and 5 mM β-glycerophosphate. Lysates were 
centrifuged at 14,000 x g for 10 minutes and protein amount was determined with 
Detergent Compatible Bradford Reagent (ThermoFisher Scientific). The volumes of 
lysates were adjusted with lysis buffer to ensure that all samples were of equal 
concentration, LDS Bolt sample buffer (Invitrogen) was added to a final concentration of 
1X, and then samples were boiled for 5 minutes @ 95oC. SDS-PAGE was performed 
with 4-12% Bis-Tris Plus polyacrylamide gels (ThermoFisher Scientific). Proteins were 
transferred to either nitrocellulose (Protran; VWR) or PVDF (Immobilin FL; EMD 
Millipore) membranes and immunoblotting was performed using the following antibodies: 
Ubiquitin (VU1, Life Sensors), K48-linked polyubiquitin (D9D5, Cell Signaling), K63-
linked polyubiquitin (D7A11, Cell Signaling), K11-linked polyubiquitin (2A3/2E6, EMD 





PSMB5 (A303-847, Bethyl), PSMB1 (D-9, Santa Cruz), Rpn6 (D1T1R,Cell Signaling), 
PSMD2 (A303-854,Bethyl), Protein Kinase G (C8A4,Cell Signaling), LaminB1 (H-90, 
Santa Cruz), PKAα catalytic subunit (A-2,Santa Cruz), PSMA6 (A303-809, Bethyl), 
Puromycin (12D10, EMD Millipore), p53 (DO-1,Santa Cruz), PSMD1 (C-7, Santa Cruz), 
α1234567 (MCP231, Enzo), GAPDH (G9545, Sigma), β-Tubulin (AA2, EMD Millipore), 
pRpt3-Thr25 (a gift from J. Dixon (11), pRpt6-S120 (a gift from G. Patrick (3), pRpn6-
S14 generated as described previously (15). Visualization was performed with the 
Odyssey CLx infrared imaging system (LiCor) and quantified with ImageStudio.    
Cell Transfection and plasmids: HEK293 cells were transfected with 0.5 μg/mL 
plasmid DNA using the PEImax reagent at a 3:1 ratio of PEImax to DNA. Media was 
replaced 5 hours after transfection. The plasmids used in this study were acquired from 
Addgene: PKAα catalytic subunits (45521) and PKG1α (16392).     
siRNA-mediated knockdown of PRKG1: ON-TARGET plus SMARTPOOL siRNA for 
PKG and Scramble were purchased from Dharmacon. Transfection was performed in 
SH-SY5Y cells for 72 hours with the Dharmafect 1 transfection reagent per 
manufacturer’s instructions. 
Subcellular fractionation: Cytoplasmic and nuclear fractions were produced as 
previously described (47), with minor changes. Briefly, cells were suspended in STM 
buffer (50 mM Tris-HCl pH 7.5, 250 mM sucrose, 5 mM MgCl2, 1 mM ATP, 0.5 mM 
PMSF, 25 nM Calyculin A, 1 mM NaF, and 1 mM β-glycerophosphate), incubated on ice 
for 30 minutes and then passed 25 times through a 21-gauge needle. The crude lysate 
was centrifuged at 800 x g for 15 minutes at 4oC. The supernatant (cytosol plus 





was resuspended in STM buffer, vortexed and centrifuged at 500 x g for 15 minutes at 
4oC. The supernatant (cell debris) was disposed and the pellet (nuclear fraction) was 
washed once more in STM buffer (1,000 x g for 10 minutes) and then resuspended in 
NET buffer (25 mM HEPES-KOH pH 7.5, 5 mM MgCl2, 100 mM NaCl, 10% glycerol, 1 
mM ATP, 0.5 mM PMSF, 25 nM Calyculin A, 1 mM NaF, and 1 mM β-
glycerophosphate). The crude nuclear fraction was incubated for 30 minutes on ice, 
sonicated, and then centrifuged at 9,000 x g for 30 minutes at 4oC. The supernatant was 
collected as the nuclear fraction. The cytosolic/mitochondrial fraction was centrifuged at 
10,000 x g for 10 minutes to remove the mitochondria and sonicated identically as the 
nuclear fraction. 5M NaCl was added to the cytosolic fraction to a final concentration of 
100 mM, to make it equimolar with the nuclear fractions. Relative protein concentration 
of cytosolic and nuclear fractions was measured by Bradford assay (ThermoFisher 
Scientific) and buffer was added to each sample to bring the fractions to the same 
relative protein concentration. 26S proteasomes were then purified from each fraction 
using the UBL-method (22). Because lower amounts of 26S proteasomes were purified 
from the nuclear fractions of SH-SY5Y cells, 26S proteasomes from the cytosolic 
fractions were diluted to the concentration obtained from the nuclear fractions. An equal 
amount of proteasomes from each fraction was used in all assays.  
Activation of PKG and ubiquitination in cytosolic fractions: The cytosolic fraction 
from HEK293 cells was prepared in STM buffer as described above, plus IBMX (45 µM). 
The reaction was prepared on ice in STM buffer plus 0.5 mM EGTA and the following 
agents were added as indicated: cGMP (Promega), Bortezomib (UBPbio)(1µM), PR-619 





agents, the samples were incubated at RT for 5 minutes, and then incubated at 37oC for 
30 minutes. The reaction was stopped by the addition of Laemmli buffer and boiling. 
Measuring deubiquitination of proteins in cytosolic fractions: HEK293 cells were 
treated for 30 minutes with 1 µM Bortezomib, and then cytosolic fraction was prepared in 
STM buffer plus IBMX. The reaction was prepared on ice in STM buffer plus 0.5 mM 
EGTA plus Bortezomib (UBPbio)(1µM), Tak243 (1µM), and cGMP (1µM) where 
indicated. The samples were vortexed, incubated at RT for 5 minutes, and then 
incubated at 37oC for the indicated times. The reaction was stopped by the addition of 
Laemmli buffer and boiling. 
Measuring activity of deubiquitinases in cell lysates: SH-SY5Y cells were treated for 
30 minutes with 100 nM of tadalafil, cinaciguat, or both and then lysed as described for 
measurements of proteasome activity. Active site modification of DUBs by HA-Ub-VS 
and hydrolysis of Ub-amc were performed as previously described (20).        
Degradation of long- or short-lived cell proteins: The degradation rate of long- or 
short-lived cell proteins was measured after labeling with [3H]phenylalanine for different 
lengths of time, and the conversion of radiolabeled cell proteins to TCA-soluble 
radiolabeled amino acids in the media was assayed as described (28). 
Affinity purification and activity measurements of 26S proteasomes: 26S 
proteasomes were purified from cells in culture and zebrafish larvae using the ubiquitin-
like domain (Ubl) method described previously (22). Cells were lysed in 25 mM HEPES-
KOH pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM ATP, 1 mM DTT, and 0.5 mM PMSF 
plus the phosphatase inhibitors, 25nM Calyculin A, 10mM NaF, and 20mM β-





previously (48), and ATPase activity was assayed using the EnzCheck Phosphate Assay 
Kit (ThermoFisher Scientific). The ATPase assay was performed at 32 oC with 2 nM 26S 
proteasomes in 100 µL of the reaction buffer: 50 mM Tris (pH 7.5), 5 mM MgCl2, 1 mM 
ATP, 1 mM DTT, 2% glycerol, and 0.1 mg/mL BSA. The rate of ATP hydrolysis was 
measured from the linear portion of the reaction. The fluorescent protein EOS was used 
to assay degradation of ubiquitinated proteins by 26S proteasomes. EOS was 
expressed, purified, ubiquitinated, and fractionated to achieve substrates of some 
uniform style as described previously (24). Polyubiquitinated EOS conjugated to 
ubiquitin chains containing 5-10 ubiquitins (50 nM) was incubated with 26S proteasomes 
(5 nM) in 20 µL reaction buffer (50 mM Tris pH 7.5, 5 mM MgCl2, 1 mM ATP, 1 mM DTT, 
10 nM Calyculin A, 1 mM NaF, 1 mM β-glycerophosphate, and 0.1 mg/mL BSA in 384-
well plates. Degradation of EOS was performed at 32 oC and was followed by the loss of 
EOS fluorescence (excitation 490 nm; emission 525 nm). 
Detecting assembled 26S proteasomes by Native PAGE: Cells were lysed by 
sonication in APB (25 mM Hepes-KOH pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10% 
glycerol, 1 mM ATP) and run on 3-8% gradient NuPAGE Tris Acetate Gels (Life 
Technologies) in Tris-Glycine Native buffer (Thermo) supplemented with 5 mM MgCl2 
and 1 mM ATP for 4 hours at 135 V at 4oC. For western blot analysis, gels were soaked 
for 15 minutes at room temperature in transfer buffer containing 48 mM Tris, 39 mM 
glycine and 0.04% SDS and then transferred to PVDF membranes in transfer buffer 
overnight at 25V at 4°C. 
Dephosphorylation of 26S proteasomes with lambda phosphatase: 26S 
proteasomes were purified by the UBL-method and incubated with either phosphatase 





phosphatase for 60 minutes at 30 OC as previously described previously (49). Peptidase 
activity was then assayed as described above. 
Phosphorylation of 26S proteasomes by PKG: Proteasomes affinity-purified by the 
UBL-method from BJ5A cells were incubated with the indicated concentrations of 
PKG1α (ThermoFisher Scientific) for 60 minutes at 30 oC in the buffer: 50 mM Tris pH 
7.5, 5 mM MgCl2, 1 mM ATP, 10 mM cGMP, 10 nM Calyculin A, 1 mM NaF, and 1 mM 
β-glycerophosphate. Peptidase activity was then measured as described above in the 
presence of the PKG inhibitor KT5823 (500 nM).  
Degradation of puromycyl polypeptides: SH-SY5Y were exposed to puromycin (5 
μg/mL) for 1 hour. The cells were then washed twice with media containing 
cycloheximide (100 μg/mL) and new media was then added containing cycloheximide 
and tadalafil (100 nM) or DMSO. At the indicated time points, cells were collected and 
flash frozen on dry ice.      
Maintenance of zebrafish stocks and transgenic lines: All zebrafish studies and 
procedures were performed under the jurisdiction of appropriate Home Office Project 
and Personal animal licenses and with local Ethics Committee approval. Zebrafish 
husbandry and experiments were performed in accordance with ARRIVE guidelines. 
Zebrafish were bred and maintained under standard conditions at 28.5 ± 0.5 °C on a 14 
h light: 10 h dark cycle. Embryos were collected in embryo medium (EM) (5 mM NaCl, 
0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM Mg2SO4, 5 mM HEPES) and staged according 
to established criteria (50). Generation of the Rho::EGFP-TauWT (Rho::EGFP-taucu7), 
Rho::EGFP-HD71Q (Rho::EGFP-HTTQ71cu5) and Rho::EGFP (Rho::EGFPcu3) was 





previously reported, was generated as described for Rho::EGFP-TauWT (36). The 
UAS::Dendra-TauA152T (Tg(UAS:Dendra2-Hsa.MAPT_A152T,myl7:EGFPcu10)) line was 
generated as previously reported (35). The pan-neuronal Gal4 driver line (hereafter 
referred to as PanN::Gal4VP16) was a kind gift from Herwig Baier (identified as line 
s1101tEt in the original publication) (52). The ubiquitous Gal4 driver line 
EIF1::Gal4VP16 (Xia.Eef1a1:GAL4-VP16cu11) was made in-house, as previously 
described (35).  
Compound treatment in zebrafish transgenic lines and Dendra-tau phenotype 
determination: Embryos were collected in EM and reared at 28.5 °C. Larvae from the 
outcross of Rho::EGFP-TauWT, Rho::EGFP-TauP301L and Rho::EGFP-HD71Q with 
wild type fish were treated from 1 day post fertilization (d.p.f.) with EM containing 0.03% 
phenylthiourea (PTU) to prevent pigmentation. At 3 d.p.f, larvae were screened for 
EGFP expression in the rod photoreceptors and then removed from PTU and reared in 
EM. Larvae were treated either with 1 µM or 10 µM sildenafil, 3 µM or 30 µM rolipram or 
0.1 % DMSO as a control from 4 to 9 d.p.f. Compounds and EM were refreshed daily. At 
9 d.p.f., larvae were anaesthetized, then fixed in 4% PFA in PBS and processed for the 
analysis of rod photoreceptor numbers or mutant HD aggregate quantification.  
Larvae expressing Dendra-TauA152T in the central nervous system 
(PanN::Gal4VP16 driver) were reared in EM until 1 d.p.f. then treated with 0.1 % DMSO, 
1 µM or 10 µM sildenafil or 3 µM or 30 µM rolipram either from 1 to 3 d.p.f. Drugs and 
medium were replenished daily. The percentage of larvae with different morphological 
phenotypes was quantified at 3 d.p.f. Phenotypes were classified either as normal; mild 





the dorsal spine but the larvae could swim straight); or severe (when fish showed a 
complete torsion of whole body in ‘U’-shape) as previously described (35).  
Western blotting from zebrafish larvae: Tissue samples from Dendra-TauA152T 
positive larvae, with the expression of Dendra-TauA152T in central nervous system at 3 
d.p.f., or Rho::EGFP-TauWT and Rho::EGFP-TauP301L larvae at 9.d.p.f. were lysed on 
ice with lysis buffer containing 1% octylglucoside, complete protease cocktail and 
PhosSTOP tablets (SIGMA). Tissue was homogenized by sonication and lysates were 
centrifuged at 7000 rpm for 1 min at 4 0C. The concentration of protein in the lysates was 
measured using the bicinchoninic acid (BCA) protein assay reagent (Pierce) with BSA as 
the standard. Supernatants were diluted in 2x Laemmli Buffer at a 1:1 dilution, resolved 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (12%) and transferred to 
PVDF membranes. The membranes were blocked with PBST containing 5% non-fat dry 
milk or 3% BSA and were then incubated overnight at 4 0C with primary antibodies 
diluted in 5% non-fat dry milk, 3% BSA or PBST. Membranes were washed three times 
in PBST for 10 min each time, incubated for 1 h at room temperature with 1:5000 dilution 
of horseradish peroxidase-conjugated secondary anti-mouse or anti-rabbit antibodies 
(DAKO) in PBST, and washed three times for 10 min each. Immunoreactive bands were 
then detected using ECL (GE Healthcare Bioscience). Quantification of proteins was 
performed using ImageJ (FIJI) software. The following antibodies were used: mouse 
anti-tau (1:1000; Abcam), mouse anti-PHF1 (1:100; a kind gift from Dr Peter Davies, 
Albert Einstein College of Medicine of Yeshiva University, NY), mouse anti-ZPR3 – anti-
rod-specific rhodopsin (1:500; ZIRC), mouse anti-ZPR1 anti-cone specific arrestin-3a 
(1:250; ZIRC) and mouse anti-Tubulin (1:1000; Sigma).  
Imaging and quantification of photoreceptors or huntingtin aggregates in central 





of Rho::EGFP-TauWT, Rho::EGFP-TauP301L or Rho::EGFP-HD71Q using a Bright 
cryostat. Sections were examined to identify the optic nerve head (central retina) and 5 
sections at the level of the optic nerve head were imaged using a Zeiss Axioplan2 
fluorescent microscope equipped with a QImaging Retiga 2000 R digital camera. 
Fluorescence images of the GFP-signal were then used to determine the number of 
photoreceptors or 71Q HD aggregates.  
RNA preparation and quantitative reverse transcription polymerase chain 
reaction: Pools of 15 embryos of Rho::EGFP fish were collected at 9 d.p.f. Total RNA 
was isolated using RNeasy-Plus Mini-Kit (Qiagen) according to the manufacturer’s 
instructions. 100 ng RNA was then used in One-Step qRT-PCR combining cDNA 
synthesis by specific-primed reverse transcription and real-time PCR reaction according 
to the manufacturer protocols (Invitrogen) using TaqMan Enzyme mix and customized 
TaqMan gene-specific primers for GAPDH (as the housekeeping gene) and GFP (from 
Applied Biosystem). All samples were run in triplicate and were analyzed on a StepOne 
Plus Real Time PCR System and StepOne Software V.2.1 (Applied Biosystem, Life 
technologies). Relative gene expression was normalized to GAPDH controls and 
assessed using 2-ΔΔCT method.  
Proteasome activity assay in lysates of zebrafish larvae: Dendra-TauA152T positive 
larvae were treated from 24 hours post fertilization (h.p.f.) with 1 M or 10 M sildenafil 
and 3 M or 30 M rolipram (1% DMSO as a control). After 24 h of drug treatment, 
larvae were culled and tissue homogenized in 50 mM Tris (pH 7.5), 1 mM DTT by brief 
sonication (twice for 10s). The assay was run with three independent samples per 
treatment, and each sample was analyzed in triplicate. Tissue lysates were centrifuged 





total protein) were loaded into a 96-well plate. Chymotrypsin-like activity of the 26S 
proteasome was monitored using a FLUOstar Omega fluorometer (BMG Labtech) with 
Omega.LNK software. The reaction was started by the addition of 100 mM Suc-LLVY-
AMC (Enzo) diluted in homogenizing buffer at the zero time point. The activity was 
assayed by measuring the fluorescence intensity during 4.5 h at 28 0C, in 5-min intervals 
(excitation 355 nm; emission 460 nm).  
Quantification of Dendra-tau clearance: Crosses of UAS::Dendra-tauA152T 
responder fish with EIF1::Gal4VP16 driver fish were performed to produce offspring 
with ubiquitous but mosaic expression of the transgene to allow visualization of 
individual neurons in the spinal cord. Embryos were sorted at 24 h.p.f. to identify 
fluorescent Dendra-TauA152T expressing individuals. Photoconversion of individual 
spinal cord neurons was performed at 2 d.p.f., as previously described (35). Briefly, 
larvae were anaesthetized by immersion in 0.2 mg/ml 3-amino benzoic acid ethyl ester 
(MS222) and mounted in 1% low melting agarose in embryo medium. Photoconversion 
of Dendra was performed by UV irradiation (405 nm) for 3 seconds using Bleachpoint 
tool and a confocal microscope Leica SP8 at x3 magnification with a 40x objective. 
Digital fluorescent images of individual neurons were taken immediately after Dendra 
photoconversion and at 6-h. The images were then analyzed using ImageJ by selecting 
regions of interest around each neuron and fluorescent intensity was measured using 
´ROI´ and Integrated Density functions. To monitor Dendra-TauA152T clearance, the 
fluorescent intensity of each cell was quantified at each time point and expressed as a 
percentage of the initial fluorescent intensity, immediately after photoconversion.  
Statistical analysis: Data are shown as mean ± SEM and were analyzed by analysis of 





hoc tests to determine differences between multiple groups in western blot densitometry 
analysis, intracellular protein degradation measurements, proteasome activity assays, 
photoreceptor counts, quantification of number of huntingtin aggregates and gene 
expression analysis. The differences between two sample groups were analyzed by the 
Student´s t-test in comparing of time points in different treatments in Dendra 
photoconversion experiments as well as activity assays with purified proteasomes. The 
differences between the phenotypes in Dendra-TauA152T larvae were analyzed by Chi-
square test. Two-way analysis of variance (Two-way ANOVA) was used to determine 
the differences between the plots of two different categorical independent variables in 
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Figure 1: Pharmacological agents that raise cGMP stimulate 26S proteasome 
activities without changing proteasome amount. 
A.) Treatment of human neuroblastoma cells (SH-SY5Y) with the PDE5 inhibitor 
tadalafil (100 nM), the sGC stimulator BAY41-2272 (100 nM), or a combination of 
the two increased proteasomal chymotrypsin-like activity in cell lysates. The 
linear rate of Suc-LLVY-AMC hydrolysis was used here and below as the 
measure of activity. In this and subsequent figures, error bars represent the 
means +/- SEM. n=4.  
B.) Levels of the 20S proteasome subunit β5 or the 19S subunit Rpn6 were not 
changed by treatments with pharmacological agents that raise cGMP. SH-SY5Y 
cells were treated with tadalafil (100 nM), BAY41-2272 (100 nM), or both, and the 
levels of proteasome subunits were analyzed by western blot. Representative 
western blots for one of three experiments is shown. 
C.) The amount of assembled 26S proteasomes was not changed by exposure of 
SH-SY5Y cells to the PDE5 inhibitor tadalafil. Cell lysates were analyzed by 
native-PAGE and western blot with an antibody against the 19S subunit Rpn1. 
The same samples were also analyzed by SDS-PAGE and western blot with an 
antibody against GAPDH to evaluate protein loading.  Representative western 





D.) After treatment of SH-SY5Y cells with these same agents (100 nM) for 30 
minutes to raise cGMP, 26S proteasomes were affinity purified by the UBL-
method and exhibited greater chymotrypsin-like, caspase-like, and trypsin-like 
activities than those from control cells. n=3 proteasome purifications. One-way 
ANOVA with Dunnett multiple comparison test. *p≤.05, **p≤.01, ***p≤.001. 
E.) 26S proteasomes purified from SH-SY5Y cells treated to raise cGMP as in 
Figure 1B hydrolyzed ATP more quickly than proteasomes from control cells. n=3 
proteasome purifications. One-way ANOVA with Dunnett multiple comparison 
test. *p≤.05, **p≤.01. 
F.) 26S proteasomes purified from SH-SY5Y cells treated with tadalafil or BAY41-
2272 as in Figure 1B degraded the fluorescent protein mEOS3.2 conjugated to a 
single K48-linked polyubiquitin chain more rapidly than proteasomes from control 
cells. n=3 proteasome purifications. One-way ANOVA with Dunnett multiple 
comparison test. *p≤.05 
Figure 2: Protein Kinase G (PKG) directly activates 26S proteasomes by 
phosphorylation 
A.) Inhibition of PKG with Rp-8-pCPT-cGMPs (1 μM) prevented the increase in 
proteasomal chymotrypsin-like activity caused by 30-minute treatment of SH-
SY5Y cells with tadalafil or BAY41-2272. n=4 samples. One-way ANOVA with 
Dunnett multiple comparison test. **p≤.01. Experiment was repeated twice with 
similar results. 
B.) 26S proteasomes purified from the cytosolic fraction of tadalafil-treated SH-SY5Y 





the activity of 26S proteasomes from the nuclear fraction. n=3 proteasome 
purifications. Student’s t test. **p≤.01 
C.) Proteasomes purified from the cytosolic fraction of cells treated for 30 minutes 
with tadalafil contained increased amounts of phosphorylated proteins. 26S 
proteasome preparations from Figure 2B were analyzed by western blot for 
phosphorylated RXXSer/Thr. The indicated bands (#) were reproducibly more 
intense in experiments from all proteasome preparation. Representative western 
blots from one of three proteasome purifications are shown. No phosphorylated 
RXXS/T bands were detected below 93 kDa. 
D.) Incubation of 26S proteasomes purified from SH-SY5Y cells with λ phosphatase 
for 1 hour eliminated all bands containing phosphorylated Ser/Thr residues 
assayed as in Figure 2B. Representative western blots from one of three 
experiments are shown. 
E.) Dephosphorylation of 26S proteasomes by λ phosphatase (shown in Figure 2D) 
reversed the increase in chymotrypsin-like activity induced by treatment of SH-
SY5Y cells with tadalafil for 30 minutes. n=3 proteasome purifications. Student’s t 
test. **p≤.01 
F.) Incubation of 26S proteasomes (5 nM) purified from human BJ5A fibroblast cells 
with increasing concentrations of PKG1α for 1 hour caused an increase in the 
phosphorylation of the indicated bands (#). Representative western blots from 
one of two experiments is shown. 
G.) After proteasomes were incubated with increasing concentrations of PKG (Figure 
2F) their chymotrypsin-like activity increased in a progressive manner. The 





H.) Agents that raise cGMP do not cause the phosphorylation of the three sites on 
the proteasome previously reported to stimulate activity: Rpn6-S14 (Lokireddy et 
al, 2015), Rpt3-Thr25 (Guo et al, 2016), and Rpt6-S120 (Djakovic et al, 2012). 
26S proteasomes purified from SH-SY5Y cells treated for 30 minutes with 
tadalafil or BAY41-2272 were analyzed by western blot for antibodies specific for 
the indicated phosphorylated subunits. Representative western blots from one of 
four proteasome purifications are shown. 
Figure 3: Raising cGMP stimulates total intracellular protein breakdown by the 
UPS 
A.) Raising cGMP stimulates the degradation of short-lived intracellular proteins. SH-
SY5Y cells were incubated for 20 minutes with 3H-phenylalanine, and then 
protein degradation was measured in the presence of cycloheximide (150 µg/mL) 
by following the conversion of 3H-labeled proteins to amino acids in the media. 
The pharmacological agents were added to the media after the labeling of cell 
proteins.  n=4. Error bars represent the means +/- SEM. 
B.) The degradation of long-lived proteins, the bulk of cell proteins, was increased by 
agents that raise cGMP. SH-SY5Y cells were exposed to 3H-phenylalanine for 16 
hours and then washed and resuspended in chase medium containing excess 
non-labeled phenylalanine for 2 hours. The conversion of radiolabeled proteins to 
labeled amino acids in the media was measured. The pharmacological agents 
were added to the media after the 2 hour chase period. Data shown are the 
slopes calculated from linear degradation rates. n=3. One-way ANOVA with 





C.) Knockdown of PKG with siRNA blocked the cGMP-mediated increase in the 
degradation of long-lived proteins. SH-SY5Y cells were exposed to scramble- or 
PRKG1- siRNA for 48 hours, and then degradation of long-lived proteins was 
measured as in Figure 3B. A representative western blot of one of three 
knockdowns of PKG is shown in Supplemental Figure 4C. n=3. One-way ANOVA 
with Dunnett multiple comparison test. ***p≤.001. 
D.) Inhibition of PKG with Rp-8-pCPT-cGMPs (1 μM) blocked the increase in the 
degradation of long-lived proteins caused by agents that raise cGMP. Protein 
degradation was measured as in Figure 3B. n=3. One-way ANOVA with Dunnett 
multiple comparison test. *p≤.05, **p≤.01, ***p≤.001. 
E.) Overexpression of PKG, but not PKA catalytic subunit, stimulated the 
degradation of long-lived proteins. HEK293 cells were transfected with cDNA 
encoding GFP, PKA catalytic subunit, or PKG 6 hours before exposure to 3H-
phenylalanine. Protein degradation was measured as in Figure 3B. n=3. One-
way ANOVA with Dunnett multiple comparison test. **p≤.01. 
F.) The muscarinic agonist carbachol (1 µM) increases the degradation of short-lived 
proteins in human fibroblasts (BJ5A) and increases degradation even further in 
the presence of the PDE5 inhibitor tadalafil. Protein degradation was measured 
as in Figure 3A, and all agents were added after the labeling of cell proteins with 
3H-phenylalanine. n=4. 
G.) Carbachol also increases the degradation of long-lived proteins in human 
fibroblasts (BJ5A) and increases degradation even further in the presence of the 
PDE5 inhibitor tadalafil. Protein degradation was measured as in Figure 3B. n=3. 





H.) Degradation of long-lived cell proteins by the proteasome was increased by 
agents that raise cGMP. Protein degradation was measured as in Figure 3B, but 
the contribution of the proteasome was measured by including in the media the 
inhibitor of lysosomal acidification concanamycin A (200 nM) one hour after 
protein labeling. n=4. One-way ANOVA with Dunnett multiple comparison test. 
*p≤.05, ***p≤.001. 
I.) Lysosomal protein degradation (autophagy) was not increased by treatments that 
raise cGMP. The degradation of long-lived proteins was measured as in Figure 
3B, and to measure the contribution of the lysosome, the proteasome inhibitor 
carfilzomib (1 µM) was added to the media in the second hour of the chase 
period and was present throughout the measurements of degradation. n=4. 
Figure 4: cGMP also rapidly increases levels of ubiquitin conjugates by 
stimulating ubiquitylation of cell proteins. 
A.) SH-SY5Y cells were treated with agents that raise cGMP and the cell lysates 
were analyzed by western blot for ubiquitin. The levels of polyubiquitinated 
proteins were quantified and representative western blots from one of three 
experiments are shown. n=3. Averages +/- SEM are shown. 
B.) The increase in ubiquitin conjugates caused by agents that raise cGMP is even 
greater in the presence of the proteasome inhibitor bortezomib. SH-SY5Y cells 
were treated for 15 minutes with these agents, lysed, and analyzed by western 
blot for ubiquitin, as in Figure 4A. Representative western blots of one of four 
experiments are shown. n=4. One-way ANOVA with Bonferroni’s multiple 





C.) Raising cGMP with tadalafil for 30 minutes in SH-SY5Y cells increases levels of 
polyubiquitinated proteins in the cytosolic fraction, but not the nuclear fraction.  
Representative western blots of one of three experiments are shown. 
D.) cGMP increases ubiquitination of cytosolic proteins in a cell-free system. 
HEK293 cells were lysed in a hypotonic buffer, and then cytosolic extracts were 
prepared by pelleting the nucleus (800 x g for 15 minutes) and mitochondria 
(10,000 x g for 10 minutes). The extracts were incubated for 30 minutes at 37oC 
with or without cGMP (1 µM) in the presence of bortezomib (1 µM), 1,10-
phenanthroline (250 µM), and PR-619 (10 µM) to prevent deubiquitination and 
proteasomal degradation of ubiquitin conjugates. Representative western blots of 
one of four experiments is shown. 
E.) cGMP does not change the rate of deubiquitination of cytosolic proteins in a cell-
free system. HEK293 cells were treated for 30 minutes with bortezomib and then 
cytosolic extracts were prepared as in (D), except an inhibitor of the ubiquitin 
activating enzyme (TAK243, 1 µM) was included instead of inhibitors of 
deubiquitinases. Representative western blot is shown of one of three 
experiments. n=3.    
Figure 5: Sildenafil and rolipram treatment stimulate proteasome activity and 
reduce the levels of toxic proteins, cell death, and morphological abnormalities in 
zebrafish models of neurodegenerative diseases 
A.) Addition of sildenafil to raise cGMP or rolipram to raise cAMP increased 
proteasome activity in wildtype fish and in fish overexpressing Dendra-tau-
A152T. Proteasomal peptidase activity in fish overexpressing Dendra-tau-A152T 





fish lysates was measured using Suc-LLVY-AMC (n=15/group) after a 1 day 
treatment. Data represent mean values +/- SEM here and below. Two-way 
ANOVA test.  **p≤.01, ***p≤.001. 
B.) Sildenafil and rolipram treatment for 6 hours increased the rate of tau clearance 
(n=50 neurons/group). In vivo tau clearance of photoconverted ‘red’ Dendra-tau 
was measured within individual neurons in the spinal cord. The measurement of 
the intensity of the photoconverted Dendra-tau signal at 6 hours relative to initial 
‘red’ intensity reflects the clearance of tau protein. Two-tailed unpaired t-test.  
**p≤.01, ***p≤.001. 
C.) The levels of hyper-phosphorylated tau relative to total tau in Dendra-tau-A152T 
fish decreased after treatment with sildenafil or rolipram (n=10/group). The 
accumulation of hyperphosphorylated tau is one of the hallmarks of tauopathies. 
Representative western blots shown in Supplemental Figure 10A. One-way 
ANOVA with post hoc Tukey’s multiple comparison test. *p≤.05, **p≤.01. 
D.) Exposure to sildenafil and rolipram for 2 days ameliorates the morphological 
defects in Dendra-tau-A152T fish. Both treatments increased the percentage of 
larvae with normal phenotypes and reduced the proportion of deformed larvae 
(n=100/treatment group). Chi-square test with confidence interval 95%. **p≤.01, 
***p≤.001. 
E.) Quantification of photoreceptors from images of sections through the central 
retina (n≥16/group) showed that both sildenafil and rolipram increased the 
survival of photoreceptors above levels in siblings treated with DMSO. 
Representative images shown in Supplemental Figure 10B. One-way ANOVA 





F.)  Sildenafil or rolipram treatment reduce the degeneration of rod photoreceptors in 
Rho::EGFP-TauWT and Rho::EGFP-TauP301L zebrafish larvae. Densitometry of 
western blots for the major rod photoreceptor protein rhodopsin (ZPR3) relative 
to the loading control arrestin (ZPR1) from 3 independent experiments 
(n=10/group). Representative western blots used for quantification are shown in 
Supplemental Figure 10C. One-way ANOVA with post hoc Tukey’s multiple 
comparison test. *p≤.05. 
G.) In Rho::EGFP-HD71Q transgenic fish, in which the expression of the mutant form 
of huntingtin exon 1 (71Q) leads to aggregate formation and degeneration of rod 
photoreceptors sildenafil and rolipram treatment decreased the number of 
huntingtin aggregates below the levels in the control (DMSO-treated) group. 
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